2025-521769-29-00招募中3 期
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Insmed Inc.
- 入组人数
- 165
- 试验地点
- 66
- 主要终点
- AEs, laboratory assessments, vital signs, physical examination, 12-lead ECG, and supplemental oxygen use
研究概览
简要总结
To evaluate the safety and tolerability of the long-term use of TPIP in participants with PHILD from Study INS1009-311
研究设计
- 分配方式
- Non Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Participants who have completed the lead-in PH-ILD TPIP Study INS1009-
- •Capable of giving signed informed consent that includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- •Agree not to participate in any other interventional trials or use investigational drugs or devices while participating in the INS1009-312 study.
排除标准
- •Participants who experienced any AEs evaluated as causally related to TPIP by the Investigator in a lead-in study , which in the opinion of the Investigator, could pose an unreasonable risk of continued treatments for the participant.
- •Current use or expected need for PAH-approved therapy, including prostacyclin, prostacyclin analogues or other prostacyclin receptor agonists, endothelin receptor antagonists, and/or soluble guanylate cyclase stimulator, or any PH-ILD approved treprostinil therapy. Use of phosphodiesterase 5 inhibitors in line with applicable guidelines is allowed.
- •Pregnant or breastfeeding. Male and female (WOCBP) participants must use contraceptives that are consistent with local regulations regarding the methods of contraception for those participating in clinical studies (contraceptive guidance is located in Section 10.4). Female participants of childbearing potential must have a negative urine pregnancy test result at trial entry before the first dose of study drug. Additional requirements for pregnancy testing during and after study intervention are located in Section 8.4.5 and Section 8.5.
- •Any medical or psychological condition, including relevant laboratory abnormalities that, in the opinion of the Investigator, may present an unreasonable risk to the study participant as a result of his/her participation in this clinical trial, may impede their ability complete the study or the study assessments or confound the outcomes of the trial.
- •Diagnosis of Pulmonary Hypertension WHO Groups 1, 2, 4, or 5, or subtypes of PH WHO Group 3 other than interstitial lung disease (including combined pulmonary fibrosis and emphysema)
- •Evidence of left ventricular failure, HFpEF or postcapillary PH
- •Platelet count <50.0 x 103/μL at Enrollment, and/or unexplained coagulation abnormalities in repeated laboratory tests.
- •Known hypersensitivity or contraindication to treprostinil or TPIP or TPIP formulation excipients (eg, mannitol, leucine).
研究组 & 干预措施
TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER
Test
干预措施: TREPROSTINIL PALMITIL INHALATION POWDER (Drug)
Placebo (inhalation powder capsules) containing 1 of 4 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg or 640 µg). The placebo product does not contain active substance and is otherwise identical to the IMP
Placebo
干预措施: Placebo (inhalation powder capsules) containing 1 of 4 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg or 640 µg). The placebo product does not contain active substance and is otherwise identical to the IMP (Drug)
结局指标
主要结局
AEs, laboratory assessments, vital signs, physical examination, 12-lead ECG, and supplemental oxygen use
AEs, laboratory assessments, vital signs, physical examination, 12-lead ECG, and supplemental oxygen use
次要结局
- Change in 6MWD measured post-dose from pre-OLE Baseline up to 104 weeks
- Absolute and percent change from pre-OLE Baseline in FVC, FVC% pred, FEV1, and FEV1% pred up to 104 weeks
- Change in NT-proBNP plasma concentration from pre-OLE Baseline up to 104 weeks
- Annualized rate of ILD exacerbations during the OLE study (104 weeks)
- Proportion of participants with a clinical worsening event. Clinical worsening events are defined as one of the following: • Hospitalization due to a cardiopulmonary indication related to the disease under study
- • Deterioration of PH-ILD, defined as a combination of the following changes from Baseline attributable to the disease under study: − decrease in 6MWD ≥15%, confirmed by 2 tests at least 4 hours but not more than 1 week apart, AND − signs/symptoms of worsened right heart failure or worsened WHO/NYHA functional class. • Lung transplantation (except for when preplanned prior to the study) • Death from any cause
- Mean change in L-PF total symptom domain score from pre-OLE Baseline up to 104 weeks Mean change from pre-OLE Baseline up to 104 weeks in: • L-PF cough domain score • L-PF dyspnea domain score • L-PF impact domain score
- Mean change from pre-OLE Baseline up to 104 weeks in: • EQ-5D-5L index score • EQ-5D-5L VAS
- Proportion of participants with a major morbidity or mortality event, defined as one of the following: • Hospitalization due to a cardiopulmonary indication related to the disease under study • Lung transplantation (except for when pre-planned prior to the study) • Death from any cause
研究者
Natasha Makulova
Scientific
Insmed Inc.
研究点 (66)
Loading locations...
相似试验
招募中
3 期
Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease2023-504471-25-00United Therapeutics Corp.319
招募中
3 期
OLE study in participants with pulmonary arterial hypertensionPulmonary Arterial Hypertension2023-505539-11-00Insmed Inc.23
尚未招募
不适用
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Pulmonary hypertension, interstitial lung diseasejRCT2031260197344
招募中
3 期
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis.Psoriatic Arthritis2022-501480-41-00Sun Pharmaceutical Industries Limited247
Enrolling By Invitation
2 期
Open-Label Extension Study to Pioneer Study 6058-SCD-101Sickle Cell DiseaseNCT07401823Fulcrum Therapeutics50